Inactive Instrument

Enzymatica AB Stock Nasdaq Stockholm

Equities

SE0003943620

Pharmaceuticals

Sales 2024 * 7.14M 77.94M Sales 2025 * 13.98M 153M Capitalization 53.87M 588M
Net income 2024 * -3M -32.75M Net income 2025 * - 0 EV / Sales 2024 * 7.83 x
Net Debt 2024 * 2.01M 21.92M Net cash position 2025 * 2.05M 22.4M EV / Sales 2025 * 3.71 x
P/E ratio 2024 *
-18.3 x
P/E ratio 2025 *
-38.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 36.72%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 59 06-12-31
Chief Executive Officer 63 17-07-17
Director of Finance/CFO 55 17-12-31
Members of the board TitleAgeSince
Chairman 62 16-12-18
Director/Board Member 56 16-02-14
Director/Board Member 57 21-04-30
More insiders
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Calendar
More about the company